MBS2320 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis2

46. Malignant rheumatoid arthritis


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03139136
(ClinicalTrials.gov)
May 30, 201726/4/2017Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid ArthritisA 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving MethotrexateRheumatoid ArthritisDrug: MBS2320;Drug: PlaceboModern Biosciences plcNULLCompleted18 Years75 YearsAll121Phase 2Georgia;Moldova, Republic of;Romania
2NCT02480946
(ClinicalTrials.gov)
July 201516/6/2015Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid ArthritisA Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With MethotrexateArthritis, RheumatoidDrug: MBS2320;Drug: Placebo;Drug: MethotrexateModern Biosciences plcCovanceCompleted18 Years70 YearsAll105Phase 1United Kingdom